The molecular mechanism of vascular endothelial growth factor (VEGF) inhibitors combined with EGFR inhibitors in the treatment of NSCLC suggests synergistic anti-tumor effects and drug resistance alleviation. Here, VEGFA is linked to non-small cell lung carcinoma.